[go: up one dir, main page]

AU2001268564A1 - Alpha-glycosylceramides for treating bacterial and fungal infections - Google Patents

Alpha-glycosylceramides for treating bacterial and fungal infections

Info

Publication number
AU2001268564A1
AU2001268564A1 AU2001268564A AU6856401A AU2001268564A1 AU 2001268564 A1 AU2001268564 A1 AU 2001268564A1 AU 2001268564 A AU2001268564 A AU 2001268564A AU 6856401 A AU6856401 A AU 6856401A AU 2001268564 A1 AU2001268564 A1 AU 2001268564A1
Authority
AU
Australia
Prior art keywords
glycosylceramides
alpha
fungal infections
treating bacterial
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268564A
Inventor
Samuel M. Behar
Michael B. Brenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2001268564A1 publication Critical patent/AU2001268564A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU2001268564A 2000-06-22 2001-06-19 Alpha-glycosylceramides for treating bacterial and fungal infections Abandoned AU2001268564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21328000P 2000-06-22 2000-06-22
US60/213,280 2000-06-22
PCT/US2001/019557 WO2001098317A2 (en) 2000-06-22 2001-06-19 Alpha-glycosylceramides for treating bacterial and fungal infections

Publications (1)

Publication Number Publication Date
AU2001268564A1 true AU2001268564A1 (en) 2002-01-02

Family

ID=22794458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268564A Abandoned AU2001268564A1 (en) 2000-06-22 2001-06-19 Alpha-glycosylceramides for treating bacterial and fungal infections

Country Status (3)

Country Link
US (1) US20020115624A1 (en)
AU (1) AU2001268564A1 (en)
WO (1) WO2001098317A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US7419958B2 (en) 2001-03-26 2008-09-02 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US8084020B2 (en) * 2002-05-01 2011-12-27 Beth Israel Deaconess Medical Center Use of anti-CD1 antibodies for the modulation of immune responses
CA2500478A1 (en) * 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
JP2006528185A (en) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1767216B1 (en) * 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSED DELIVERY
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (en) * 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 Mature dendritic cell compositions and methods for culturing same
ES2378076T3 (en) * 2004-11-02 2012-04-04 The Board Of Trustees Of Leland Stanford Junior University Methods for inhibition of NKT cells
US9295722B2 (en) * 2005-01-28 2016-03-29 The Scripps Research Institute Bacterial glycolipid activation of CD1d-restricted NKT cells
US8076484B2 (en) * 2005-08-11 2011-12-13 Georgia Health Science University Research Institute, Inc. Modified green tea polyphenol formulations
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
SI2056842T1 (en) 2006-04-07 2013-02-28 The Scripps Research Institute Modified-galactosyl ceramide for the treatment of cancerous diseases
WO2007127218A2 (en) * 2006-04-26 2007-11-08 Taro Pharmaceuticals U.S.A., Inc. Streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20080014192A1 (en) * 2006-05-23 2008-01-17 Poeta Maurizio D Methods For The Diagnosis And Treatment of Fungal Infections Caused By Microorganisms Producing Glucosylceramide
JP5564672B2 (en) * 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート Adjuvant and method of using the same
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2008350531B2 (en) * 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
CN102215864A (en) * 2008-10-08 2011-10-12 威蒂赛尔公司 Vaccine composition for use against influenza
US20170224790A1 (en) * 2014-10-01 2017-08-10 KOHJIN Life Sciences Co., Ltd. Fungal glucosylceramide as a vaccine for fungal infections
WO2016077388A1 (en) * 2014-11-10 2016-05-19 Cheng-Wei Chang Aminoglycosides, methods of synthesis, and associated applications

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0761940B2 (en) * 1986-11-17 1995-07-05 株式会社資生堂 Liposomal formulation for outer skin
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (en) * 1992-07-16 1995-11-01 Kirin Brewery
JPH09315980A (en) * 1996-05-24 1997-12-09 Kirin Brewery Co Ltd AIDS onset preventive drug and progression inhibitor
GB9614889D0 (en) * 1996-07-16 1996-09-04 John P Robarts Research Inst T Ceramide promoters of haematopoiesis
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
ES2235324T3 (en) * 1997-04-10 2005-07-01 Kirin Beer Kabushiki Kaisha EMPLOYMENT OF A-GLYCOSILCERAMIDS FOR THE OBTAINING OF A THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES.
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides

Also Published As

Publication number Publication date
WO2001098317A3 (en) 2002-09-26
US20020115624A1 (en) 2002-08-22
WO2001098317A2 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
AU2001268564A1 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2003290867A1 (en) Methods and products for treating staphylococcal infections
WO2003088897A3 (en) Fab i inhibitors
EP1241577A3 (en) Methods and arrangements for improved parity-stripe processing
AU2003299561A1 (en) Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
WO2002044989A8 (en) Method and system for dynamically maintaining internet associations
AU2001232647A1 (en) Methods and devices for treating stuttering problems
IL160010A0 (en) Methods and compositions for treating fungal infections
AU2003279526A1 (en) Identifying and treating vaginal infections
AU2002211717A1 (en) Stresscopins and their uses
AU2001279850A1 (en) Method and arrangement for studsystem
AU2000262575A1 (en) Method for localising direction and localisation arrangement
AU2001231155A1 (en) Microbes and methods for remediation
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2003239132A1 (en) Methods and compositions for preventing and treating microbial infections
AU2002353774A1 (en) Products and methods for treating microbial infections
AU3985499A (en) Lytic enzymes useful for treating fungal infections
AU2001233932A1 (en) Method and composition
AU2001271400A1 (en) Bioelastomer nanomachines and biosensors
AU1923501A (en) Pyridinones to treat and prevent bacterial infections
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections
AU2001291308A1 (en) Methods and compositions for treating nail fungus
AU2003290506A1 (en) Methods and devices for treating severe peripheral bacterial infections